MedTrace Logo

Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris

NCT07320872 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-01-06

No results posted yet for this study

Summary

Psoriasis is a common immune-mediated inflammatory skin disease affecting at least 100 million individuals worldwide. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3% of the Egyptian people.

It is associated with poor quality of life, reduced life expectancy and multimorbidity including psoriatic arthritis, obesity and cardiovascular disease.

Vaspin (VASP, SERPIN 12) is a recently discovered adipokine that has been isolated from the visceral adipose tissue of a rat model of type 2 diabetes. It is coded by the gene SERPNA12 located on the long arm of chromosome 14q32.13 and consists of six exons and five introns.

Conditions

  • Psoriasis Vulgaris

Interventions

BIOLOGICAL

vaspin gene polymorphism

to detect the correlation between vaspin gene polymorphism and serum vaspin levels among psoriasis patients. * To detect the relationship between the risk of psoriasis and the vaspin gene polymorphism. * To detect correlation between vaspin gene polymorphism and the severity of psoriasis.

Sponsors & Collaborators

  • Aswan University

    lead OTHER

Principal Investigators

  • Moustafa Adam Ali El Taieb, Professor · Dermatology, Venereology and Andrology.Faculty of Medicine, Aswan University

  • Hoda Soltan Sherkawy El Bakry, Lecturer · Medical biochemistry,Faculty of Medicine,Aswan University

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-10
Primary Completion
2026-08-10
Completion
2026-08-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07320872 on ClinicalTrials.gov